Dispatch Bio
Philadelphia
About Dispatch Bio
Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options. The company helps to create a world where all cancer patients can be cured through innovative treatment technologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $216.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2025)
- Website: dispatchbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dispatch-bio-52806 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.